JG
ACAD icon

Jefferies Group’s Acadia Pharmaceuticals ACAD Stock Holding History

Jefferies Group’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-12,500
Closed -$176K – 1610
2022
Q2 		$176K Buy
+12,500
New +$233K ﹤0.01% 1295
2021
Q2 		– Sell
-10,400
Closed -$268K – 1623
2021
Q1 		$268K Buy
+10,400
New +$458K ﹤0.01% 1271
2018
Q4 		– Sell
-30,500
Closed -$633K – 2114
2018
Q3 		$633K Buy
+30,500
New +$480K ﹤0.01% 1530
2018
Q1 		– Sell
-22,500
Closed -$677K – 2191
2017
Q4 		$677K Sell
22,500
-5,200
-19% -$166K ﹤0.01% 1582
2017
Q3 		$1.04M Sell
27,700
-32,700
-54% -$1.06M 0.01% 1268
2017
Q2 		$1.69M Sell
60,400
-156,500
-72% -$4.66M 0.01% 1023
2017
Q1 		$7.46M Buy
+216,900
New +$7.66M 0.06% 354
2016
Q2 		– Sell
-6,000
Closed -$168K – 2093
2016
Q1 		$168K Buy
+6,000
New +$131K ﹤0.01% 1878
2015
Q2 		– Sell
-6,300
Closed -$205K – 3276
2015
Q1 		$205K Buy
+6,300
New +$217K ﹤0.01% 1756
2014
Q1 		– Sell
-218,600
Closed -$5.46M – 1989
2013
Q4 		$5.46M Buy
218,600
+1,800
+0.8% +$42.5K 0.03% 294
2013
Q3 		$5.96M Buy
216,800
+6,800
+3% +$142K 0.06% 287
2013
Q2 		$3.81M Buy
+210,000
New +$2.89M 0.04% 314

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jefferies Group's ACAD Position: Q3 2022 in Review

Jefferies Group sold out of Acadia Pharmaceuticals (ACAD) in Q3 2022, closing a stake of 48,424 shares — an estimated $682K sold.

Jefferies Group first reported a position in ACAD in Q2 2013 and held it in 27 quarters. The position peaked at $4.02M in Q3 2017. 222 funds tracked by Wall St. Rank hold ACAD as of Q3 2022.

  • Jefferies Group reported no remaining Acadia Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Jefferies Group sold 48,424 Acadia Pharmaceuticals shares in Q3 2022, an estimated $682K.
  • Jefferies Group first reported a position in Acadia Pharmaceuticals in Q2 2013 and held it in 27 quarters.
  • Jefferies Group's Acadia Pharmaceuticals position peaked at $4.02M in Q3 2017.
  • 222 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2022.

Based on Jefferies Group's 13F filing for Q3 2022, filed 14 Nov 2022.